Viralkumar Shah
Concepts (308)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 112 | 2026 | 3776 | 16.540 |
Why?
| | Hypoglycemic Agents | 64 | 2026 | 1365 | 11.680 |
Why?
| | Blood Glucose | 78 | 2026 | 2269 | 9.140 |
Why?
| | Blood Glucose Self-Monitoring | 61 | 2026 | 697 | 8.040 |
Why?
| | Insulin Infusion Systems | 36 | 2026 | 460 | 6.750 |
Why?
| | Insulin | 49 | 2026 | 2482 | 6.550 |
Why?
| | Hypoglycemia | 27 | 2026 | 463 | 6.010 |
Why?
| | Diabetes Mellitus, Type 2 | 21 | 2025 | 2526 | 3.910 |
Why?
| | Pancreas, Artificial | 9 | 2025 | 98 | 3.160 |
Why?
| | Biosimilar Pharmaceuticals | 5 | 2024 | 27 | 2.960 |
Why?
| | Insulin Glargine | 7 | 2025 | 84 | 2.950 |
Why?
| | Diabetes Mellitus | 11 | 2025 | 1074 | 2.710 |
Why?
| | Diabetic Retinopathy | 5 | 2026 | 200 | 2.580 |
Why?
| | Osteoporotic Fractures | 6 | 2020 | 61 | 2.540 |
Why?
| | Insulin Aspart | 5 | 2024 | 29 | 2.500 |
Why?
| | Bone Density | 11 | 2025 | 494 | 2.340 |
Why?
| | Fractures, Bone | 8 | 2024 | 404 | 2.340 |
Why?
| | Adult | 91 | 2026 | 39177 | 2.090 |
Why?
| | Diabetic Ketoacidosis | 4 | 2022 | 208 | 1.990 |
Why?
| | Hyperglycemia | 8 | 2024 | 361 | 1.970 |
Why?
| | Humans | 149 | 2026 | 141187 | 1.760 |
Why?
| | Middle Aged | 62 | 2026 | 34434 | 1.470 |
Why?
| | Hyperparathyroidism, Primary | 5 | 2014 | 7 | 1.470 |
Why?
| | Consensus | 4 | 2024 | 704 | 1.460 |
Why?
| | Young Adult | 47 | 2026 | 13673 | 1.390 |
Why?
| | Female | 81 | 2026 | 75515 | 1.310 |
Why?
| | Male | 77 | 2026 | 69783 | 1.300 |
Why?
| | Diabetes Complications | 4 | 2020 | 223 | 1.240 |
Why?
| | Peptides | 2 | 2025 | 978 | 1.200 |
Why?
| | Femur Neck | 4 | 2022 | 63 | 1.190 |
Why?
| | Obesity | 5 | 2025 | 3004 | 1.180 |
Why?
| | Adolescent | 39 | 2026 | 22007 | 0.980 |
Why?
| | Pregnancy in Diabetics | 2 | 2025 | 123 | 0.910 |
Why?
| | Marijuana Abuse | 2 | 2019 | 231 | 0.900 |
Why?
| | Liraglutide | 1 | 2024 | 31 | 0.890 |
Why?
| | Cannabis | 3 | 2022 | 512 | 0.880 |
Why?
| | Glucose | 6 | 2023 | 1041 | 0.880 |
Why?
| | Treatment Outcome | 17 | 2026 | 11120 | 0.860 |
Why?
| | Glucagon-Like Peptides | 1 | 2025 | 60 | 0.850 |
Why?
| | Risk Factors | 18 | 2024 | 10438 | 0.840 |
Why?
| | Insulin, Long-Acting | 3 | 2021 | 64 | 0.810 |
Why?
| | Sweetening Agents | 1 | 2023 | 56 | 0.780 |
Why?
| | Bone and Bones | 2 | 2023 | 317 | 0.780 |
Why?
| | Bone Remodeling | 2 | 2020 | 77 | 0.770 |
Why?
| | Gastroparesis | 2 | 2019 | 9 | 0.760 |
Why?
| | Registries | 10 | 2021 | 2135 | 0.760 |
Why?
| | Vitamin D | 3 | 2014 | 397 | 0.750 |
Why?
| | Cardiovascular Diseases | 6 | 2022 | 2087 | 0.750 |
Why?
| | Ketosis | 1 | 2022 | 12 | 0.730 |
Why?
| | RNAi Therapeutics | 1 | 2021 | 6 | 0.730 |
Why?
| | Hyperoxaluria, Primary | 1 | 2021 | 13 | 0.720 |
Why?
| | Insulins | 1 | 2022 | 37 | 0.720 |
Why?
| | Patient Satisfaction | 2 | 2025 | 695 | 0.700 |
Why?
| | Automobile Driving | 1 | 2023 | 151 | 0.680 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2024 | 264 | 0.670 |
Why?
| | Osteoporosis | 3 | 2020 | 244 | 0.660 |
Why?
| | Incretins | 1 | 2020 | 21 | 0.660 |
Why?
| | Blindness | 1 | 2020 | 48 | 0.640 |
Why?
| | Aged | 29 | 2026 | 24574 | 0.640 |
Why?
| | Diabetes, Gestational | 1 | 2024 | 320 | 0.640 |
Why?
| | Bone Resorption | 1 | 2020 | 84 | 0.630 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 2 | 2025 | 48 | 0.620 |
Why?
| | Feasibility Studies | 1 | 2024 | 1018 | 0.620 |
Why?
| | Hip Fractures | 1 | 2020 | 86 | 0.610 |
Why?
| | Self-Management | 2 | 2020 | 205 | 0.600 |
Why?
| | Age Factors | 6 | 2020 | 3292 | 0.600 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2019 | 42 | 0.590 |
Why?
| | Osteogenesis | 1 | 2020 | 199 | 0.580 |
Why?
| | Child | 24 | 2026 | 22308 | 0.570 |
Why?
| | Absorptiometry, Photon | 5 | 2025 | 266 | 0.570 |
Why?
| | Self Care | 2 | 2018 | 395 | 0.560 |
Why?
| | Parathyroid Hormone | 4 | 2014 | 111 | 0.550 |
Why?
| | Bone Diseases | 1 | 2018 | 66 | 0.550 |
Why?
| | Quality of Life | 5 | 2026 | 2999 | 0.540 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 285 | 0.530 |
Why?
| | Body Mass Index | 6 | 2025 | 2382 | 0.510 |
Why?
| | Drugs, Investigational | 1 | 2017 | 32 | 0.510 |
Why?
| | Calcium | 6 | 2014 | 1187 | 0.500 |
Why?
| | Fractures, Spontaneous | 1 | 2015 | 16 | 0.480 |
Why?
| | Marijuana Smoking | 1 | 2019 | 263 | 0.480 |
Why?
| | Accidental Falls | 1 | 2018 | 198 | 0.470 |
Why?
| | Retrospective Studies | 15 | 2026 | 16273 | 0.460 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 2 | 2025 | 9 | 0.460 |
Why?
| | Vitamin D Deficiency | 2 | 2014 | 190 | 0.450 |
Why?
| | Weight Loss | 3 | 2025 | 789 | 0.450 |
Why?
| | Gallstones | 1 | 2014 | 33 | 0.420 |
Why?
| | Case-Control Studies | 7 | 2026 | 3588 | 0.410 |
Why?
| | Glucose Intolerance | 1 | 2015 | 147 | 0.410 |
Why?
| | Cross-Sectional Studies | 9 | 2025 | 5636 | 0.410 |
Why?
| | Insulin Lispro | 2 | 2024 | 41 | 0.400 |
Why?
| | Prospective Studies | 10 | 2025 | 7739 | 0.400 |
Why?
| | Longitudinal Studies | 4 | 2025 | 2902 | 0.390 |
Why?
| | Pancreatitis | 1 | 2014 | 136 | 0.390 |
Why?
| | Suicide | 1 | 2020 | 670 | 0.380 |
Why?
| | Clinical Trials as Topic | 3 | 2026 | 1052 | 0.370 |
Why?
| | Bone Diseases, Metabolic | 3 | 2019 | 64 | 0.360 |
Why?
| | Sex Factors | 5 | 2025 | 2058 | 0.360 |
Why?
| | United States | 11 | 2025 | 15220 | 0.360 |
Why?
| | Diabetic Angiopathies | 3 | 2020 | 251 | 0.360 |
Why?
| | Prediabetic State | 2 | 2025 | 248 | 0.360 |
Why?
| | Gastrointestinal Tract | 1 | 2014 | 204 | 0.350 |
Why?
| | Surveys and Questionnaires | 5 | 2026 | 5929 | 0.350 |
Why?
| | Bromocriptine | 2 | 2025 | 31 | 0.340 |
Why?
| | Meals | 3 | 2024 | 132 | 0.330 |
Why?
| | Autoimmune Diseases | 1 | 2015 | 464 | 0.330 |
Why?
| | Islet Amyloid Polypeptide | 2 | 2025 | 48 | 0.330 |
Why?
| | Sex Characteristics | 3 | 2025 | 788 | 0.320 |
Why?
| | Drug Therapy, Combination | 2 | 2025 | 1040 | 0.320 |
Why?
| | Benchmarking | 2 | 2022 | 188 | 0.310 |
Why?
| | Pregnancy | 6 | 2025 | 7070 | 0.310 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2025 | 133 | 0.300 |
Why?
| | History, 20th Century | 4 | 2025 | 329 | 0.300 |
Why?
| | Autoantibodies | 2 | 2018 | 1470 | 0.280 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2025 | 1556 | 0.280 |
Why?
| | Cross-Over Studies | 5 | 2025 | 578 | 0.280 |
Why?
| | Diabetic Nephropathies | 2 | 2024 | 299 | 0.280 |
Why?
| | Reference Values | 2 | 2019 | 805 | 0.260 |
Why?
| | Prevalence | 5 | 2023 | 2772 | 0.260 |
Why?
| | India | 4 | 2015 | 208 | 0.260 |
Why?
| | Phenotype | 1 | 2015 | 3166 | 0.260 |
Why?
| | Metformin | 2 | 2025 | 333 | 0.250 |
Why?
| | Risk Assessment | 3 | 2020 | 3490 | 0.250 |
Why?
| | Follow-Up Studies | 4 | 2026 | 5200 | 0.240 |
Why?
| | Solid Waste | 1 | 2025 | 3 | 0.240 |
Why?
| | Thyrotoxicosis | 1 | 2024 | 8 | 0.220 |
Why?
| | Manitoba | 1 | 2024 | 4 | 0.220 |
Why?
| | Smartphone | 1 | 2025 | 91 | 0.220 |
Why?
| | Phosphates | 3 | 2014 | 181 | 0.220 |
Why?
| | History, 21st Century | 3 | 2025 | 220 | 0.210 |
Why?
| | Proof of Concept Study | 1 | 2024 | 85 | 0.210 |
Why?
| | ROC Curve | 1 | 2025 | 586 | 0.210 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 77 | 0.210 |
Why?
| | Drug Substitution | 1 | 2024 | 60 | 0.210 |
Why?
| | Artificial Organs | 1 | 2023 | 2 | 0.210 |
Why?
| | Algorithms | 3 | 2024 | 1763 | 0.200 |
Why?
| | Germany | 2 | 2020 | 132 | 0.200 |
Why?
| | Glycemic Index | 1 | 2022 | 26 | 0.190 |
Why?
| | Cost-Benefit Analysis | 1 | 2025 | 618 | 0.190 |
Why?
| | Minority Groups | 2 | 2023 | 278 | 0.180 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2022 | 32 | 0.180 |
Why?
| | Reproducibility of Results | 5 | 2024 | 3348 | 0.180 |
Why?
| | Gastric Emptying | 1 | 2021 | 36 | 0.180 |
Why?
| | Computer Systems | 2 | 2018 | 51 | 0.180 |
Why?
| | Aged, 80 and over | 5 | 2021 | 7856 | 0.170 |
Why?
| | Exercise | 2 | 2025 | 2103 | 0.170 |
Why?
| | Vision Screening | 1 | 2021 | 46 | 0.170 |
Why?
| | Calibration | 2 | 2018 | 152 | 0.170 |
Why?
| | Body Composition | 1 | 2025 | 701 | 0.170 |
Why?
| | Diabetic Neuropathies | 1 | 2022 | 94 | 0.170 |
Why?
| | Incidence | 2 | 2026 | 2794 | 0.170 |
Why?
| | Biomarkers | 3 | 2023 | 4174 | 0.170 |
Why?
| | Glucagon-Like Peptide 2 | 1 | 2020 | 7 | 0.170 |
Why?
| | Regression Analysis | 2 | 2020 | 1020 | 0.170 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2020 | 14 | 0.170 |
Why?
| | Austria | 1 | 2020 | 8 | 0.170 |
Why?
| | Double-Blind Method | 1 | 2025 | 1983 | 0.160 |
Why?
| | Skiing | 1 | 2021 | 51 | 0.160 |
Why?
| | Energy Intake | 1 | 2023 | 513 | 0.160 |
Why?
| | Vision Disorders | 1 | 2021 | 157 | 0.160 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 1973 | 0.160 |
Why?
| | Societies, Medical | 1 | 2024 | 855 | 0.160 |
Why?
| | Machine Learning | 1 | 2025 | 553 | 0.160 |
Why?
| | Glucagon-Secreting Cells | 1 | 2020 | 23 | 0.160 |
Why?
| | Psychometrics | 2 | 2021 | 739 | 0.160 |
Why?
| | RNA Interference | 1 | 2021 | 469 | 0.160 |
Why?
| | Time Factors | 4 | 2026 | 6956 | 0.160 |
Why?
| | Injections, Subcutaneous | 1 | 2020 | 165 | 0.160 |
Why?
| | Body Weight | 1 | 2024 | 996 | 0.150 |
Why?
| | Insulin Antibodies | 1 | 2020 | 103 | 0.150 |
Why?
| | Bone Development | 1 | 2019 | 54 | 0.150 |
Why?
| | Postprandial Period | 1 | 2020 | 111 | 0.150 |
Why?
| | Fatal Outcome | 1 | 2020 | 309 | 0.150 |
Why?
| | C-Peptide | 1 | 2020 | 167 | 0.150 |
Why?
| | Sodium-Glucose Transporter 2 | 2 | 2021 | 26 | 0.150 |
Why?
| | Radius | 1 | 2019 | 51 | 0.150 |
Why?
| | Healthy Volunteers | 1 | 2019 | 214 | 0.150 |
Why?
| | Infusion Pumps, Implantable | 1 | 2018 | 26 | 0.150 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 227 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 878 | 0.140 |
Why?
| | Cancellous Bone | 1 | 2018 | 26 | 0.140 |
Why?
| | Methyldopa | 1 | 2018 | 7 | 0.140 |
Why?
| | Social Class | 1 | 2020 | 268 | 0.140 |
Why?
| | Pelvic Bones | 1 | 2020 | 128 | 0.140 |
Why?
| | Postmenopause | 1 | 2020 | 371 | 0.140 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 45 | 0.140 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 250 | 0.140 |
Why?
| | Tibia | 1 | 2019 | 183 | 0.130 |
Why?
| | HLA-DQ Antigens | 1 | 2018 | 178 | 0.130 |
Why?
| | Health Behavior | 1 | 2023 | 790 | 0.130 |
Why?
| | Artificial Intelligence | 1 | 2021 | 334 | 0.130 |
Why?
| | Health Status Disparities | 1 | 2020 | 297 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2022 | 371 | 0.130 |
Why?
| | Child, Preschool | 4 | 2026 | 11457 | 0.130 |
Why?
| | Computer-Aided Design | 1 | 2017 | 41 | 0.130 |
Why?
| | Uric Acid | 1 | 2018 | 164 | 0.130 |
Why?
| | Glucagon | 1 | 2017 | 104 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2018 | 220 | 0.130 |
Why?
| | Hormones | 1 | 2017 | 140 | 0.130 |
Why?
| | Antibody Formation | 1 | 2018 | 298 | 0.130 |
Why?
| | Biosensing Techniques | 1 | 2018 | 138 | 0.120 |
Why?
| | Immunity, Cellular | 1 | 2018 | 269 | 0.120 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1597 | 0.120 |
Why?
| | Telemedicine | 1 | 2025 | 891 | 0.120 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 168 | 0.120 |
Why?
| | Alkaline Phosphatase | 2 | 2014 | 149 | 0.120 |
Why?
| | Drug Design | 1 | 2017 | 168 | 0.120 |
Why?
| | Referral and Consultation | 1 | 2021 | 798 | 0.120 |
Why?
| | Health Personnel | 1 | 2022 | 737 | 0.120 |
Why?
| | Drug Overdose | 1 | 2020 | 353 | 0.120 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 382 | 0.120 |
Why?
| | Automation | 2 | 2025 | 100 | 0.110 |
Why?
| | Circadian Rhythm | 1 | 2019 | 508 | 0.110 |
Why?
| | Energy Metabolism | 1 | 2020 | 932 | 0.110 |
Why?
| | Parathyroidectomy | 1 | 2014 | 9 | 0.110 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.110 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 7 | 0.110 |
Why?
| | Allylamine | 1 | 2013 | 7 | 0.100 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2013 | 11 | 0.100 |
Why?
| | Insulin Detemir | 1 | 2013 | 8 | 0.100 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2014 | 60 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2018 | 566 | 0.100 |
Why?
| | Insulin, Isophane | 1 | 2013 | 21 | 0.100 |
Why?
| | Sulfonylurea Compounds | 1 | 2013 | 49 | 0.100 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2013 | 107 | 0.100 |
Why?
| | Bionics | 2 | 2023 | 14 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2892 | 0.100 |
Why?
| | Parathyroid Neoplasms | 1 | 2012 | 12 | 0.100 |
Why?
| | Mutation | 1 | 2024 | 4013 | 0.100 |
Why?
| | Thiazolidinediones | 1 | 2013 | 138 | 0.100 |
Why?
| | Suppuration | 1 | 2012 | 9 | 0.100 |
Why?
| | Abdominal Pain | 1 | 2014 | 145 | 0.100 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 177 | 0.100 |
Why?
| | Recurrence | 1 | 2016 | 1110 | 0.100 |
Why?
| | Hypoparathyroidism | 1 | 2012 | 7 | 0.090 |
Why?
| | Diabetic Foot | 1 | 2012 | 24 | 0.090 |
Why?
| | Cohort Studies | 2 | 2020 | 5799 | 0.090 |
Why?
| | Dogs | 1 | 2013 | 427 | 0.090 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2012 | 68 | 0.090 |
Why?
| | Hemoglobins | 1 | 2014 | 361 | 0.090 |
Why?
| | Leptin | 1 | 2013 | 242 | 0.090 |
Why?
| | Soft Tissue Infections | 1 | 2012 | 40 | 0.090 |
Why?
| | Cholelithiasis | 1 | 2011 | 37 | 0.090 |
Why?
| | Swine | 1 | 2013 | 806 | 0.080 |
Why?
| | Biomedical Research | 1 | 2017 | 703 | 0.080 |
Why?
| | Adenoma | 1 | 2012 | 220 | 0.080 |
Why?
| | Osteomyelitis | 1 | 2012 | 139 | 0.080 |
Why?
| | Heart Failure | 1 | 2023 | 2088 | 0.080 |
Why?
| | Animals | 4 | 2018 | 37657 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2018 | 2002 | 0.080 |
Why?
| | Colorado | 1 | 2019 | 4610 | 0.070 |
Why?
| | Staphylococcal Infections | 1 | 2012 | 392 | 0.070 |
Why?
| | Pilot Projects | 3 | 2021 | 1820 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1396 | 0.060 |
Why?
| | Recycling | 1 | 2025 | 8 | 0.060 |
Why?
| | Citric Acid Cycle | 1 | 2024 | 58 | 0.060 |
Why?
| | Disease Progression | 2 | 2026 | 2793 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2023 | 103 | 0.050 |
Why?
| | Life Style | 1 | 2025 | 482 | 0.050 |
Why?
| | Socioeconomic Factors | 2 | 2017 | 1306 | 0.050 |
Why?
| | Insulin, Regular, Human | 1 | 2022 | 48 | 0.050 |
Why?
| | Needles | 1 | 2022 | 63 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1865 | 0.040 |
Why?
| | Off-Label Use | 1 | 2021 | 53 | 0.040 |
Why?
| | Reference Standards | 1 | 2021 | 186 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1086 | 0.040 |
Why?
| | Pancreas | 1 | 2023 | 326 | 0.040 |
Why?
| | Sodium | 1 | 2021 | 196 | 0.040 |
Why?
| | Monitoring, Ambulatory | 1 | 2020 | 90 | 0.040 |
Why?
| | Inpatients | 1 | 2023 | 507 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 42 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 167 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 338 | 0.030 |
Why?
| | Individuality | 1 | 2019 | 162 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 696 | 0.030 |
Why?
| | Skin | 1 | 2022 | 765 | 0.030 |
Why?
| | Kidney | 1 | 2024 | 1482 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 556 | 0.030 |
Why?
| | Social Determinants of Health | 1 | 2020 | 269 | 0.030 |
Why?
| | Prognosis | 1 | 2025 | 4073 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 322 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 600 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 433 | 0.030 |
Why?
| | Creatinine | 1 | 2018 | 489 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2024 | 1225 | 0.030 |
Why?
| | Patient Compliance | 1 | 2020 | 610 | 0.030 |
Why?
| | Hospitalization | 1 | 2025 | 2255 | 0.030 |
Why?
| | Culture | 1 | 2015 | 130 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2064 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2014 | 30 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2018 | 750 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 633 | 0.030 |
Why?
| | Cholecalciferol | 1 | 2014 | 61 | 0.030 |
Why?
| | Home Care Services | 1 | 2017 | 259 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2172 | 0.030 |
Why?
| | Calcifediol | 1 | 2012 | 33 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2180 | 0.020 |
Why?
| | Parents | 1 | 2021 | 1434 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2746 | 0.020 |
Why?
| | Drug Resistance, Bacterial | 1 | 2012 | 192 | 0.020 |
Why?
| | Tourniquets | 1 | 2011 | 32 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2012 | 370 | 0.020 |
Why?
| | Research Design | 1 | 2017 | 1143 | 0.020 |
Why?
| | Serum Albumin | 1 | 2011 | 153 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 1122 | 0.020 |
Why?
| | Fasting | 1 | 2011 | 284 | 0.020 |
Why?
| | Infant | 1 | 2019 | 9818 | 0.010 |
Why?
| | Mice | 1 | 2018 | 18048 | 0.010 |
Why?
|
|
Shah's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|